An observational study in Elderly, Acute Inflammatory Response and Iron Deficiency, sponsored by Centre Hospitalier Régional d'Orléans. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by Centre Hospitalier Régional d'Orléans · Observational
In elderly adults, anemia is common and multifactorial. Inflammation, which is frequently observed in hospitalized elderly patients, profoundly alters iron metabolism, making it difficult to accurately assess true iron status.
The objective of this study is to identify a predictive model that can estimate iron deficiency status in the absence of inflammation using transferrin saturation (TSAT) measured during an inflammatory phase. This model could help distinguish true iron deficiency from anemia of inflammation, improve patient management, and reduce decision-making delays.
The study will be conducted in two distinct phases: a pilot phase involving up to 200 patients at a single center in France, followed by a main phase involving 1,523 patients across multiple centers in France. Participants will be adults aged over 75 years who are hospitalized in a geriatric ward and present with an acute inflammatory episode (C-reactive protein [CRP] > 50 mg/L).
In addition to routine analyses performed during hospitalization, supplementary laboratory analyses will be carried out. Following admission in hospital, patients will receive standard medical care. Upon admission or on the following day, patients, their trusted representative, or relatives will be informed about the study. If eligibility criteria are met, the patient will be enrolled.
Research-specific laboratory analyses will be performed on blood samples collected at 4 times:
In elderly adults, anemia is common and multifactorial. Inflammation, which is frequently observed in hospitalized elderly patients, profoundly alters iron metabolism, making it difficult to accurately assess true iron status.
The objective of this study is to identify a predictive model that can estimate iron deficiency status in the absence of inflammation using transferrin saturation (TSAT) measured during an inflammatory phase. This model could help distinguish true iron deficiency from anemia of inflammation, improve patient management, and reduce decision-making delays.
The study will be conducted in two distinct phases:
The primary objective of the pilot phase is to estimate the proportion of patients with iron deficiency, defined as a transferrin saturation (TSAT) \< 20%, in order to confirm the prevalence assumption that will be used in the sample size calculation for the development of a predictive model of iron deficiency in the absence of inflammation.
The primary objective of the main phase is to develop and validate a predictive model for iron deficiency, defined according to the TSAT threshold in a non-inflammatory setting, with non-inflammation defined as a C-reactive protein (CRP) level \< 10 mg/L (or \< 20 mg/L depending on results of the pilot phase). The model will be based on measurements obtained during an acute inflammatory state in order to predict iron deficiency.
Eligible participants will be patients aged over 75 years who are hospitalized and present an acute inflammatory episode (CRP > 50 mg/L).
In addition to the routine examinations performed during hospitalization, supplementary analyses will be conducted. After admission (Day -1), patients will receive standard care from the medical team. On the day of admission (Day -1) or the following day (Day 0), patients, their trusted representatives, or relatives will be informed about the study. If the patient fulfils the eligibility criteria, he will be enrolled in the study.
Research-specific analyses will be performed on the following blood samples:
These additional analyses will be performed using routine blood samples collected during standard clinical monitoring and will not require any additional blood samples. They constitute the main research-specific intervention beyond standard clinical practice.
The objective is to develop a simple and validated tool to estimate transferrin saturation (TSAT), and potentially ferritin levels, in the absence of inflammation using data obtained during the acute inflammatory phase. This tool could help shorten hospital stays, optimize iron therapy prescribing, and improve the management of hospitalized elderly patients.
386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 77 observational studies indexed under Iron Deficiencies.
Browse Iron Deficiencies studies →Centre Hospitalier Régional d'Orléans is the lead sponsor of 132 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Eligible patients will be recruited from among elderly adults hospitalized for acute condition associated with a biologically documented inflammatory syndrome and for whom laboratory follow-up can be performed during and after the acute inflammatory episode.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hospitalized patients aged \>75 years admitted to hospital with an acute inflammatory episode (CRP \> 50 mg/L).
Diagnostic Test: Analysis of biological parameters
Research-specific analyses will be performed on the following blood samples: * Day 0 : reticulocyte count, reticulocyte hemoglobin content (Ret-He), percentage of hypochromic red blood cells, Delta-He, serum iron, transferrin, transferrin saturation (TSAT, %), ferritin, soluble transferrin receptor, and hepcidin. * CRP \< 20 mg/L (pilot phase only): reticulocyte count, reticulocyte hemoglobin content, percentage of hypochromic red blood cells, Delta-He, serum iron, transferrin, TSAT (%), ferritin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), total bilirubin, albumin, and creatine phosphokinase (CPK). * CRP \< 10 mg/L: reticulocyte count, reticulocyte hemoglobin content, percentage of hypochromic red blood cells, Delta-He, serum iron, transferrin, TSAT (%), ferritin, , AST, ALT, AP, total bilirubin, albumin, and CPK. * 5 days after CRP \< 10 mg/L: same as CRP \< 10 mg/L
Proportion of patients with iron deficiency, defined as transferrin saturation < 20% (pilot phase)
To estimate the proportion of patients with iron deficiency, defined as transferrin saturation (TSAT) \< 20%, in order to validate the prevalence assumption that will be used in the sample size calculation for the development of a predictive model of iron deficiency under non-inflammatory conditions
Time frame: From enrollment to the end of study at 4 weeks maximum
To develop a predictive model for iron deficiency, defined by TSAT under non-inflammatory conditions (defined as CRP<10 mg/L or <20 mg/L, depending on results of pilot phase), using measurements obtained during acute inflammatory episode (main phase)
Transferrin saturation (TSAT) will be measured at baseline and when CRP \< 10 mg/L (or \< 20 mg/L, depending on results of the pilot phase). Iron deficiency will be defined as a TSAT \< 20%. The predictive performance of the model for estimating TSAT under non-inflammatory conditions and the agreement between predicted and observed TSAT values under non-inflammatory conditions will be assessed.
Time frame: From enrollment to the end of study at 4 weeks maximum
Proportion of patients with CRP < 20 mg/L and proportion of patients with CRP < 10 mg/L in the study population (pilot phase)
To estimate the proportion of patients with CRP \< 20 mg/L and the proportion of patients with CRP \< 10 mg/L, in order to refine the study population for the development of the predictive model of iron deficiency under non-inflammatory conditions.
Time frame: From enrollment to the end of study at 4 weeks maximum
Among the clinically relevant variables, and within subgroups of patients with CRP < 20 mg/L and < 10 mg/L (pilot phase), to examine a/the collinearity structure among potential predictors ; b/the distribution of categorical variables
For collinearity: Associations between candidate predictors will first be assessed through bivariate analyses (Spearman's or Pearson's correlation coefficient for two continuous variables, Cramér's V for two categorical variables, and point-biserial correlation for a continuous/binary variable pair), using a predefined alert threshold of \|r\| or V \> 0.7. A variance inflation factor (VIF) will then be calculated for each predictor retained after this initial step; variables with a VIF \> 5 will be excluded. For rare categories: Frequency distributions will be examined for each categorical variable. A category will be considered too rare if it represents less than 5% of the subgroup sample size.
Time frame: From enrollment to the end of study at 4 weeks maximum
To assess the correlation between transferrin saturation measured during an inflammatory state and transferrin saturation measured under non-inflammatory conditions.
Correlation between transferrin saturation measured during inflammation (baseline sample) and transferrin saturation measured once C-reactive protein (CRP) levels have decreased to \< 10 mg/L.
Time frame: From enrollment to the end of study at 4 weeks maximum
To develop and validate a predictive model for iron deficiency, defined by ferritin levels under non-inflammatory conditions, with non-inflammation defined as CRP < 10 mg/L (or < 20 mg/L, depending on the results of the pilot phase).
Ferritin will be assessed at baseline and when CRP is \< 10 mg/L (or \< 20 mg/L, depending on the results of the pilot phase). Iron deficiency will be defined by a ferritin level \< 100 µg/L. The predictive performance of the model for estimating ferritin under non-inflammatory conditions and the agreement between predicted and observed ferritin values under non-inflammatory conditions will be assessed.
Time frame: From enrollment to the end of study at 4 weeks maximum
To assess the evolution of iron status parameters when CRP < 10mg/l and 5 days post CRP < 10mg/l.
Iron status parameters assessed when CRP \< 10mg/l and 5 days post CRP \< 10mg/l.
Time frame: From enrollment to the end of study at 4 weeks maximum
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Régional d'Orléans →